
|Articles|July 1, 2004
Therapeutic options for sexual dysfunction still growing
Do you think the three available phosphodiesterase type-5 inhibitors-vardenafil hydrochloride (Levitra), tadalafil (Cialis), and sildenafil citrate (Viagra)-are essentially the same, or do they have distinct advantages in the treatment of ED?
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer
2
Farah Rahman, MD, on monitoring resident wellness using biofeedback
3
Veda Giri, MD, on patient-reported outcomes with prostate cancer genetic testing
4
Pearls & Perspectives: Innovation and Evolving Pathways in Female Pelvic Medicine, with Raveen Syan, MD, FPMRS
5






